文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

哈萨克斯坦三种新型全口服短程方案治疗利福平耐药或耐多药结核的安全性与有效性

Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.
PubMed 文献 · Clin Infect Dis · 2024-01-01

在哈萨克斯坦公共卫生机构开展的前瞻性队列研究,纳入510例肺结核MDR/RR-TB患者,分别接受含Bdq-Lzd-Lfx并加用Cs/Cfz、Dlm/Z或Dlm/Cfz的9个月全口服方案。452例未排除者中治疗成功率分别为92%、89%和100%,临床相关特殊关注不良事件不常见。

要点

  • 三种9个月全口服方案在MDR/RR-TB患者中显示良好安全性和有效性。
  • Cs/Cfz组治疗成功率92%(95% CI: 89-95%),Dlm/Z组89%(95% CI: 80-94%),Dlm/Cfz组100%(95% CI: 86-100%)。
  • 临床相关特殊关注不良事件不常见。

核心结论

  • 所有方案均显示出极好的安全性和有效性,扩大了患者、提供者和规划的治疗选择。

研究设计与样本

  • 前瞻性队列研究,在哈萨克斯坦公共卫生机构的操作研究条件下纳入开始治疗肺结核MDR/RR-TB的患者。
  • 共510例参与者,41%为女性,中位年龄37岁(第25-75百分位:28-49),18%体重指数<18.5 kg/m2,51%有空洞性疾病。
  • 399例(78%)启动Bdq-Lzd-Lfx-Cs-Cfz,83例(16%)启动Bdq-Lzd-Lfx-Dlm-Z,28例(5%)启动Bdq-Lzd-Lfx-Dlm-Cfz。
  • 58例(11%)被排除,最常见原因为基线耐药(n=52;90%);排除者接受更长方案治疗。

主要发现

  • 剩余452例参与者中,Cs/Cfz方案治疗成功率为92%(95% CI: 89-95%),Dlm/Z方案为89%(95% CI: 80-94%),Dlm/Cfz方案为100%(95% CI: 86-100%)。
  • 临床相关特殊关注不良事件不常见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2019, the World Health Organization called for operational research on all-oral shortened regimens for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We report safety and effectiveness of three 9-month all-oral regimens containing bedaquiline (Bdq), linezolid (Lzd), and levofloxacin (Lfx) and reinforced with cycloserine (Cs) and clofazimine (Cfz), delamanid (Dlm) and pyrazinamide (Z), or Dlm and Cfz. METHODS: We conducted a prospective cohort study of patients initiating treatment for pulmonary MDR/RR-TB under operational research conditions at public health facilities in Kazakhstan. Participants were screened monthly for adverse events. Participants with baseline resistance were excluded from the study and treated with a longer regimen. We analyzed clinically relevant adverse events of special interest in all participants and sputum culture conversion and end-of-treatment outcomes among individuals who were not excluded. RESULTS: Of 510 participants, 41% were women, the median age was 37 years (25th-75th percentile: 28-49), 18% had a body mass index <18.5 kg/m2, and 51% had cavitary disease. A total of 399 (78%) initiated Bdq-Lzd-Lfx-Cs-Cfz, 83 (16%) started Bdq-Lzd-Lfx-Dlm-Z, and 28 (5%) initiated Bdq-Lzd-Lfx-Dlm-Cfz. Fifty-eight individuals (11%) were excluded from the study, most commonly due to identification of baseline drug resistance (n = 52; 90%). Among the remaining 452 participants, treatment success frequencies were 92% (95% CI: 89-95%), 89% (95% CI: 80-94%), and 100% (95% CI: 86-100%) for regimens with Cs/Cfz, Dlm/Z, and Dlm/Cfz, respectively. Clinically relevant adverse events of special interest were uncommon. CONCLUSIONS: All regimens demonstrated excellent safety and effectiveness, expanding the potential treatment options for patients, providers, and programs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rashitov M, Franke MF, Trevisi L, et al. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan. Clin Infect Dis. 2024. PMID: 38833593. doi:10.1093/cid/ciae305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。